Daewoong Pharmaceutical: "Nabota" Effective Against Teeth Grinding During Sleep

[Asia Economy Reporter Cho Hyun-ui] Daewoong Pharmaceutical announced on the 30th that its botulinum toxin product 'Nabota' has been found to be effective in alleviating teeth grinding symptoms during sleep.

According to Daewoong Pharmaceutical, the clinical results of the related researchers were published in Toxins, a Science Citation Index (SCI)-level journal.

In this clinical study, administering Nabota to patients who grind their teeth during sleep confirmed its effect in reducing the strength of the masseter muscle, which influences teeth grinding. The masseter is one of the masticatory muscles located on the side of the jaw.

Professor Kim Seong-taek's team from Yonsei University College of Dentistry's Department of Oral Medicine conducted a randomized, double-blind, placebo-controlled study to verify the effect of botulinum toxin on sleep bruxism by administering Nabota and a placebo.

The researchers administered Nabota or placebo to the masseter muscle and measured the intensity of force applied to the masseter during maximum voluntary clenching (MVC) and repetitive masticatory muscle activity (RMMA) using electromyography through polysomnography (PSG), which assesses sleep disorder severity. The measurement periods were immediately after Nabota administration, and at 4 and 12 weeks post-administration.

The study results showed that subjects who received Nabota had weakened masseter muscle strength compared to the placebo group, alleviating teeth grinding symptoms such as chewing behavior, with effects maintained for 12 weeks. No serious drug-related adverse events were reported.

Park Seong-su, head of Nabota Business Division at Daewoong Pharmaceutical, explained, “This study served as an opportunity to confirm Nabota's additional potential not only in aesthetics but also in therapeutic fields.”

This content was produced with the assistance of AI translation services.